These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32806551)

  • 1. 1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel.
    Modi K; Lawson S; Chen G; Tumuluri D; Rekhtman I; Kurtz M; Brailoiu GC; Chen QH; Lakshmikuttyamma A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
    Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
    Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers.
    Shome R; Ghosh SS
    ACS Appl Bio Mater; 2021 Jun; 4(6):5033-5048. PubMed ID: 35007052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells.
    Chandrasekaran J; Balasubramaniam J; Sellamuthu A; Ravi A
    J Pharm Pharmacol; 2021 Apr; 73(6):749-757. PubMed ID: 33769483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
    Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
    Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer.
    Srinivasan A; Thangavel C; Liu Y; Shoyele S; Den RB; Selvakumar P; Lakshmikuttyamma A
    Mol Carcinog; 2016 May; 55(5):743-56. PubMed ID: 25968914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disarib, a Specific BCL2 Inhibitor, Induces Apoptosis in Triple-Negative Breast Cancer Cells and Impedes Tumour Progression in Xenografts by Altering Mitochondria-Associated Processes.
    Manjunath M; Ravindran F; Sharma S; Siddiqua H; Raghavan SC; Choudhary B
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendrosomal nanocurcumin and exogenous p53 can act synergistically to elicit anticancer effects on breast cancer cells.
    Baghi N; Bakhshinejad B; Keshavarz R; Babashah S; Sadeghizadeh M
    Gene; 2018 Sep; 670():55-62. PubMed ID: 29753810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol enhances the sensitivity of FL118 in triple-negative breast cancer cell lines via suppressing epithelial to mesenchymal transition.
    Yar Saglam AS; Kayhan H; Alp E; Onen HI
    Mol Biol Rep; 2021 Jan; 48(1):475-489. PubMed ID: 33389483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines.
    Kundur S; Prayag A; Selvakumar P; Nguyen H; McKee L; Cruz C; Srinivasan A; Shoyele S; Lakshmikuttyamma A
    J Cell Physiol; 2019 Jul; 234(7):11103-11118. PubMed ID: 30478904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells.
    Al-Howail HA; Hakami HA; Al-Otaibi B; Al-Mazrou A; Daghestani MH; Al-Jammaz I; Al-Khalaf HH; Aboussekhra A
    BMC Cancer; 2016 Jul; 16():540. PubMed ID: 27465411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
    Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
    Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
    Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
    Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
    Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N
    Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT.
    Hu C; Li M; Guo T; Wang S; Huang W; Yang K; Liao Z; Wang J; Zhang F; Wang H
    Phytomedicine; 2019 May; 58():152740. PubMed ID: 31005718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
    Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells.
    Kashyap A; Umar SM; Dev J R A; Prasad CP
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2177-2184. PubMed ID: 34319041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition.
    Garcia E; Luna I; Persad KL; Agopsowicz K; Jay DA; West FG; Hitt MM; Persad S
    Sci Rep; 2021 Jun; 11(1):11757. PubMed ID: 34083676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.